Isoniazid appeared to offer exciting possibilities in the treatment of uveitis when the drug became available in 1952, because tuberculosis was then considered to be the chief cause of endogenous uveitis. Gordon (i960), however, stated that tuberculosis was rarely, if ever, a cause of uveitis, and the number of cases attributed to tuberculosis has been steadily declining (Table I) ; the present estimate, both in our clinic (Schlaegel, I969) and in that of Witmer (I964) in Zurich is only I per cent. Some have argued that tubercle bacilli must be present to produce a tuberculous uveitis (Woods, 1954) , but others have felt that in many cases the condition may be due to an allergic reaction (Ashton, I955) . Convincing cases of allergic origin are those that occur 2 or more days after a tuberculin skin test. The results of the present study, which reports a disappointing response of uveitis to isoniazid, pertain only to the presumed infectious type. Material and methods
The isoniazid double-blind test was at first used as a routine diagnostic measure in all cases of uveitis, but was later restricted to those thought most likely to be of tuberculous aetiology. Both placebo and isoniazid tablets were made on the same machine by the same company* and the bottles were labelled by the pharmacy so that the doctors, nurses, and patients did not know whether the placebo or the active isoniazid (Ioo mg.) was being administered.
After the patient had been examined, he was instructed to take one tablet three times a day and to return for a check in 2 weeks. The bottles were randomized so that about half the patients began treatment with isoniazid and about half with the placebo. A treatment period of 2 weeks was chosen since experiments on animals usually showed a response beginning on about the sixth day of T. F. Schlaegel, Jr., and J. C. Weber treatment (Woods, Becker, and Wood, 1954; Knapp and von Sallmann, 1954) . We (Schlaegel and Hungerford, 1954); Woods (I954) also had the impression that clinical improvement usually began after I or 2 weeks of therapy.
At the second visit, the patient was again examined and it was decided whether he had responded to treatment (+) or not (-). He was then given the companion bottle and again instructed to take one tablet three times a day and to return for another check in 2 weeks. At the third visit it was again decided whether the uveitis had improved (+) or not (-).
After this final grading the pharmacy revealed the order in which the placebo and active isoniazid had been administered. Some potential errors inherent in this experimental design are shown in Table II 
Discussion
These results fit in with the declining emphasis on the role of tuberculosis in the aetiology of uveitis. This study does not concern those types of uveitis presumed to be due to allergy to the tubercle bacilli or its products, but only the infectious types. Table IV shows that allergic tuberculous uveitis is unlikely to occur very frequently, since the incidence of a positive tuberculin reaction in uveitis patients was, if anything, less than in a control group. A26 group.bmj.com on April 9, 2017 -Published by http://bjo.bmj.com/ Downloaded from Summary 33 control subjects and 344 patients with uveitis (selected from those most likely to have tuberculosis) were given either isoniazid or placebo iOO mg. three times a day for two consecutive periods of 2 weeks. The tablets were all exactly the same and neither the patient nor the doctor knew which of the two drugs was administered first and which second. The patients were examined after each 2-week course of therapy. Of the 344 uveitis patients, 38 improved on the isoniazid and failed to improve on the placebo, and 38 improved on the placebo and failed to improve on isoniazid; 58 improved on both, and 2IO did not improve at all. The results in the 33 control subjects were not statistically different. This evidence suggests that infectious tuberculosis is rarely a cause of endogenous uveitis. 
